"54" . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@en . . "Yan-Rong Luo" . . . . . "Jian-Min Wang" . . . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@nl . "Hong Zhou" . . "30337697" . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u0436\u043E\u0432\u0442\u043D\u0456 2018"@uk . . . . . "scientific article published on 19 October 2018"@en . . . . . . . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@en . . "Hong-Mei Li" . . "Lei Gao" . . . . . . . . . . . . "2018-10-19T00:00:00Z"^^ . . . . "Wei-Ping Zhang" . "Dan Yang" . . . . . . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@nl . "Xiong Ni" . "Xian-Min Song" . . . . . . . . . . "Hui Cheng" . . . . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@en . . . . . . . . . . "Xiao-Xia Hu" . . . . . . . "Jie Chen" . "wetenschappelijk artikel"@nl . "im Oktober 2018 ver\u00F6ffentlichter wissenschaftlicher Artikel"@de . . . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@en . "art\u00EDculu cient\u00EDficu espubliz\u00E1u n'ochobre de 2018"@ast . . "6" . . . . . . . . . . . "10.1038/S41409-018-0356-5" . . "Zi-Wei Wang" . . "Jian-Min Yang" . "Li Chen" . . . . . . . . . . . . . . . . . . . "Xin-Xin Xia" . "Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study"@nl . . . . . "894-902" . . . . . . . . .